Feb 13 (Reuters) - Johnson & Johnson ( JNJ ) on Thursday
said it will discontinue a late-stage study of an experimental
E.coli vaccine that it was developing in partnership with Sanofi
.
The drugmaker said its decision was based on the
recommendation of an independent committee that found the
vaccine candidate may not be sufficiently effective.